Figure 4.
Plasma n-6 PUFA metabolites influenced by n-3 DPA supplementation. A) Plasma concentrations of AA (20:4, n-6)-derived (series 2) PGs in response to 7-d DPA supplementation. B) Plasma isoprostane F2aVI levels in response to 7 d supplementation with OO, EPA, or DPA. C) Plasma levels of 5(S),6(S)-DiHETE, a nonenzymatic degradation product of LTA4 in response to 7 d supplementation with OO, EPA, or DPA. D) Plasma concentrations of DGLA (20:3, n-6)-derived (series 1) PGs in response to 7 d DPA supplementation. Value are means ± sem. *P < 0.05 vs. d 0 within the respective supplementation period; #P < 0.05 vs. placebo OO supplementation at the same time point.
